A RANDOMIZED, CONTROLLED PHASE III TRIAL OF SORAFENIB WITH OR WITHOUT CONVENTIONAL TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (STAH)

被引：2
|
作者：
Park, J. -W. [1 ]
Kim, Y. J. [2 ]
Kim, D. Y. [3 ]
Bae, S. H. [4 ]
Yeon, J. E. [5 ]
Han, S. Y. [6 ]
Hwang, J. S. [7 ]
Lee, Y. -J. [8 ]
Cheong, J. Y. [9 ]
Kwon, O. S. [10 ]
Kim, H. Y. [11 ]
Lee, H. C. [12 ]
Heo, J. [13 ]
Kim, B. H. [1 ]
Paik, S. W. [14 ]
机构：
[1] Natl Canc Ctr, Goyang, South Korea
[2] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[3] Severance Hosp, Seoul, South Korea
[4] Catholic Univ Hosp Korea, Seoul, South Korea
[5] Korea Univ, Guro Hosp, Seoul, South Korea
[6] Dong A Univ, Med Ctr, Busan, South Korea
[7] Keimyung Univ, Dongsan Med Ctr, Daegu, South Korea
[8] Busan Paik Hosp, Busan, South Korea
[9] Ajou Univ Hosp, Suwon, South Korea
[10] Gachon Univ, Gil Hosp, Inchon, South Korea
[11] Boramae Med Ctr, Seoul, South Korea
[12] Asan Med Ctr, Seoul, South Korea
[13] Busan Natl Univ Hosp, Busan, South Korea
[14] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
来源：
JOURNAL OF HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
10.1016/S0168-8278(15)31514-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1335
引用
收藏
页码：S857 / S857
页数：1
相关论文
共 50 条
  • [41] Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization
    Fan, Wenzhe
    Zhu, Bowen
    Zheng, Xinlin
    Yue, Shufan
    Lu, Mingjian
    Fan, Huishuang
    Qiao, Liangliang
    Li, Fuliang
    Yuan, Guosheng
    Wu, Yanqin
    Zou, Xinhua
    Wang, Hongyu
    Xue, Miao
    Li, Jiaping
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (05) : 1873 - 1882
  • [42] Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
    Baur, Johannes
    Ritter, Christian O.
    Germer, Christoph-Thomas
    Klein, Ingo
    Kickuth, Ralph
    Steger, Ulrich
    HEPATIC MEDICINE-EVIDENCE AND RESEARCH, 2016, 8 : 69 - 74
  • [43] Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization
    Wenzhe Fan
    Bowen Zhu
    Xinlin Zheng
    Shufan Yue
    Mingjian Lu
    Huishuang Fan
    Liangliang Qiao
    Fuliang Li
    Guosheng Yuan
    Yanqin Wu
    Xinhua Zou
    Hongyu Wang
    Miao Xue
    Jiaping Li
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 1873 - 1882
  • [44] SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
    Zhu, Andrew X.
    Rosmorduc, Olivier
    Evans, T. R. Jeffry
    Ross, Paul J.
    Santoro, Armando
    Carrilho, Flair Jose
    Bruix, Jordi
    Qin, Shukui
    Thuluvath, Paul J.
    Llovet, Josep M.
    Leberre, Marie-Aude
    Jensen, Markus
    Meinhardt, Gerold
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) : 559 - 566
  • [45] Comparison of efficacy between sorafenib monotherapy vs. transarterial chemoembolization - sorafenib sequential therapy in hepatocellular carcinoma patients with extrahepatic metastatis - An interim analysis of randomized controlled trial
    Yim, H. J.
    Suh, S. J.
    Jung, Y. K.
    Cho, S. B.
    Chung, W. J.
    Kim, Y. S.
    Bae, S. H.
    Park, J. Y.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S210 - S211
  • [46] Sorafenib versus transarterial chemoembolization plus external beam radiotherapy in patients with hepatocellular carcinoma with major vascular invasion (START): a randomized phase 2 trial
    Yoon, Sang Min
    Lee, So Jung
    Kim, Jong Hoon
    Shin, Ji Hoon
    An, Jihyun
    Lee, Danbi
    Shim, Ju Hyun
    Lee, Han Chu
    Ryoo, Baek-Yeol
    Lim, Young-Suk
    HEPATOLOGY, 2017, 66 : 729A - 729A
  • [47] Regorafenib Combination Therapy in Advanced Hepatocellular Carcinoma: With or without Transarterial Chemoembolization
    Cao, Lei
    Lu, Xiangyu
    Chen, Haoqing
    Yu, Xiang
    Li, Jinze
    Peng, Yi
    Gu, Lu
    Feng, Ji
    Xie, Ping
    Liu, Yaben
    ONCOLOGY, 2024,
  • [48] Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC).
    Ciuleanu, Tudor-Eliade
    Bazin, Igor
    Lungulescu, Dan
    Miron, Lucian
    Bondarenko, Igor
    Deptala, Andrzej
    Rodriguez-Torres, Maribel
    Giantonio, Bruce J.
    Sun, Weijing
    Fox, Norma Lynn
    Aktan, Gursel
    Wissel, Paul Stephen
    Egger, Jacki
    Ding, Meichun
    Kalyani, Rubana
    Gribbin, Matthew Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] Sorafenib plus tislelizumab as maintenance therapy for patients with advanced hepatocellular carcinoma treated with transarterial chemoembolization: A phase II study.
    Cai, Mingyue
    Hong, Xiaoyang
    Huang, Wensou
    Guo, Yongjian
    Shi, Wenbo
    Liang, Licong
    Zhou, Jingwen
    Lin, Liteng
    Chen, Ye
    Zhu, Kangshun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 574 - 574
  • [50] Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial
    Han, Guohong
    Yang, Jijin
    Shao, Guoliang
    Teng, Gaojun
    Wang, Maoqiang
    Yang, Jianyong
    Liu, Zhaoyu
    Feng, Gansheng
    Yang, Renjie
    Lu, Ligong
    Chao, Yee
    Wang, Jianhua
    FUTURE ONCOLOGY, 2013, 9 (03) : 403 - 410
12345